Erenumab
- Generic Name
- Erenumab
- Brand Names
- Aimovig
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1582205-90-0
- Unique Ingredient Identifier
- I5I8VB78VT
- Background
Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines. Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specificall...
- Indication
Erenumab is indicated for the preventative treatment of migraine in adults .
- Associated Conditions
- Migraine
- Associated Therapies
- -
Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 89
- Registration Number
- NCT02575833
- Locations
- 🇨🇭
Research Site, Geneva 14, Switzerland
To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients
- Conditions
- Interventions
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2019-06-03
- Lead Sponsor
- Amgen
- Target Recruit Count
- 35
- Registration Number
- NCT02542605
- Locations
- 🇳🇱
Research Site, Leiden, Netherlands
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention
- First Posted Date
- 2015-06-29
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 577
- Registration Number
- NCT02483585
- Locations
- 🇨🇭
Research Site, Zollikon, Switzerland
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
- First Posted Date
- 2015-05-28
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 955
- Registration Number
- NCT02456740
- Locations
- 🇬🇧
Research Site, Stoke on Trent, United Kingdom
A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 609
- Registration Number
- NCT02174861
- Locations
- 🇬🇧
Research Site, Stoke on Trent, United Kingdom
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
- Conditions
- Interventions
- First Posted Date
- 2013-09-30
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 483
- Registration Number
- NCT01952574
- Locations
- 🇸🇪
Research Site, Vällingby, Sweden
Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine Patients
- First Posted Date
- 2012-11-08
- Last Posted Date
- 2019-01-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 48
- Registration Number
- NCT01723514
- Locations
- 🇧🇪
Research Site, Leuven, Belgium
Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients
- First Posted Date
- 2012-09-20
- Last Posted Date
- 2019-01-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 61
- Registration Number
- NCT01688739
- Locations
- 🇧🇪
Research Site, Leuven, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.